伊立替康单药治疗复发耐铂上皮性卵巢癌疗效观察  

The efficacy observation of irinotecan in treatment of recurrent epithelial ovailan carcinoma

作　　者：于荣[1] 侯建青[2] 

机构地区：[1]烟台毓璜顶医院莱山分院妇科,烟台市264000 [2]烟台毓璜顶医院妇科

出　　处：《滨州医学院学报》2010年第6期443-444,共2页Journal of Binzhou Medical University

摘　　要：目的观察伊立替康单药化疗方案治疗复发的耐铂上皮性卵巢癌的临床疗效。方法选择33例复发的耐铂上皮性卵巢癌,采用伊立替康单药化疗方案治疗,伊立替康80 mg/m2,静脉给药,第1、8、15天,28 d为1周期。2至4个周期结束后评价疗效。结果 33例均可评价疗效,总有效率为27.3%,中位肿瘤进展时间为6.8个月;毒副反应主要为骨髓抑制和迟发性腹泻,无化疗毒性相关死亡病例。结论伊立替康单药是临床上治疗复发的耐铂上皮性卵巢癌安全有效的方案。Objective To observe the efficacy and toxicity of irinotecan treating the patients with recurrent epithelial ovarian carcinoma.Methods 33 cases with recurrent epithelial ovarian carcinoma were enroll.Irinotecan 80 mg/m2 infusion 1,8,15 dag,and repeated every 28 days.Results The over all response rates（ORR） and median TTP were 27.3% and 6.8 months respectively.The main toxicities were myelosuppression,tardive diarrhea,and no patients dead for toxic reactions of chemotherapy.Conclusion Irinotecan haplo drug regimen is a utility and safe regimen for recurrent epithelial ovarian Carcinoma.

关 键 词：卵巢癌 伊立替康 化疗 

分 类 号：R730.53[医药卫生—肿瘤] R737.31[医药卫生—临床医学]